Frederic Desdouits Appointed CEO of Orano Med

Orano has appointed Frederic Desdouits as the Chief Executive Officer of its subsidiary Orano Med, a biotechnology company pioneering the development of targeted alpha therapies in oncology.

Nicolas Maes, CEO of the Orano group, said, “The extensive experience of Frederic Desdouits in the pharmaceutical industry, particularly in the biotechnology sector, will be a valuable asset in accelerating the development of the clinical portfolio as well as the deployment of Orano Med’s industrial platform. As a member of the Governance Board since 2022, he already has a deep understanding of Orano Med’s activities and challenges, which will facilitate his swift involvement in strategic decision-making.”

Experience

Prior to joining Orano, Desdouits served as CEO of TreeFrog Therapeutics, a French biotech company specializing in stem cell-based therapies. He previously led the pharmaceutical activities of Seqens, a leader in the manufacturing of specialty ingredients, and oversaw business development as well as U.S. pharmaceutical operations at Pierre Fabre. Earlier, he co-founded Bionest Partners, a strategy and financial consulting firm specializing in healthcare, and headed Exane BNP Paribas’ European pharmaceutical and biotech financial analysis team. He began his career in pharmaceutical research.

Desdouits graduated from the École Polytechnique, obtained a PhD in neurosciences from the University of Paris VI Sorbonne, before going on to do postdoctoral research at the Rockefeller University in New York.

“I am pleased to join the Orano Med team at a pivotal moment in its development. The biotech company has unique scientific and industrial assets to accelerate innovation in the field of radioligand therapy,” Desdouits remarked. “Our dynamic development positions us among the global leaders in the emerging field of targeted alpha therapy. Together with the entire team, I am fully committed to turning this potential into tangible benefits for patients.”